Current location:Cultural Compass news portal > opinions
Healthgen embraces biotech breakthrough
Cultural Compass news portal2024-05-21 13:43:13【opinions】3People have gathered around
IntroductionAs the first of its kind in the world, plant-derived recombinant human serum albumin developed by a
As the first of its kind in the world, plant-derived recombinant human serum albumin developed by a Chinese biotechnology company is set to be industrialized and commercialized, bringing new hope to patients.
In February, Wuhan Healthgen Biotechnology Corp announced that it had successfully completed phase III clinical trials for plant-derived recombinant human serum albumin for hypoalbuminemia patients. According to the results, its curative efficacy was not inferior to plasma-derived human serum albumin in terms of safety and tolerance.
Human serum albumin is among several indispensable therapeutic biologics for various diseases, an essential emergency medicine for hospitals, and a key excipient for biopharmaceuticals. It is also widely used in vaccine production, supplements for cell culture media and other fields.
At present, human serum albumin drugs used in clinical practice are all prepared from human plasma, as has been the case since World War II. Nowadays, there is an increasing public health concern with plasma-derived HSA (pHSA) with its potential risk for transmission of blood-derived infectious pathogens such as hepatitis and HIV, as well as amid plasma resource shortages. Data from industry research company ChinaIRN.com showed that China's annual demand for human serum albumin was between 1,500 and 1,800 tons, among which over 60 percent had to be imported from outside China. Once the plant-derived recombinant human serum albumin is launched in the market, the supply and demand imbalance of human serum albumin in China will be effectively relieved.
Healthgen Biotechnology said it plans to submit a new drug application this year, and the product is expected to be approved and launched in the market as early as next year. So far, the company has gained a drug manufacturing certificate issued by the Hubei medical products administration, and its intelligent manufacturing is capable of producing 10 tons of plant-derived recombinant human serum albumin and 1 million doses of formulations annually. It is planning on building an industrial base capable of producing 120 tons of plant-derived recombinant human serum albumin and 12 million doses of formulations annually, which will guarantee supply once the product is launched.
Healthgen Biotech's plant-derived recombinant human serum albumin project was approved as a National Science and Technology Major Project for New Drug Development. The Center for Drug Evaluation (CDE) in China said that the technology developed by the company is an original innovative technology and has promising application prospects, offering a new path for medicine production.
Yang Daichang, chairman of Healthgen Biotech, began research and development of plant-derived recombinant human serum albumin in 2005.
"Rice has been a staple food consumed by humans for thousands of years. Humans have a high tolerance to proteins in rice. Meanwhile, it can prevent the transmission risk of various viruses or pathogens carried by plasma. Through genetic engineering, we introduced the human serum albumin gene into the rice genome, making the rice a 'bioreactor' or 'protein production plant'. During the process of rice grain filling and maturation, human serum albumin is continuously synthesized and accumulated in rice grains. Finally, human serum albumin is extracted and purified from rice grain," Yang said.
You Xi, co-founder of Beijing-based consultancy Communication Planet, said: "Plant-derived recombinant human serum albumin has broad application prospects, and the success in its phase III clinical trial showcased the progress that China's biotechnology companies have made in R&D capability and independent innovation. Prior to that, there had been no breakthroughs in solving high clinical dosages, high requirements for safety, costs, large-scale production and environmental protection problems of human serum albumin."
You said: "Currently, Chinese biotechnology companies' innovative capabilities are gradually improving, and are taking a leading role in the world in some fields. Yet efforts are still needed to bridge the gap between China and the world in the overall biotech sector."
The National Medical Products Administration said that in 2023, 82 innovative medicines were approved, among which 39 were developed by domestic companies, setting a record high.
Healthgen Biotech said that in the future, it plans to step up efforts to promote the global commercialization of plant-derived recombinant human serum albumin products, as well as the expansion of indications for core pipelines and the R&D progress of other pipelines under development.
Address of this article:http://saintlucia.popular-vines.com/content-92d699815.html
Very good!(5)
Related articles
- Lynn Williams breaks NWSL goal
- Man makes shocking 100
- AAPI Heritage Month: The origin and what it means
- Parma secures promotion back into Serie A after 3 seasons in Italy's second division
- Who is Jacob Zuma, the former South African president disqualified from next week's election?
- Student protests take over some campuses. At others, attention is elsewhere
- Starbucks lowers guidance, promises new drinks and deals after customer traffic fell in weak Q2
- Dozens of protesters against so
- French sports minister calls for sanctions after Monaco player tapes over anti
- Video shows Robert De Niro rehearsing for a Netflix series, not yelling at anti
Popular articles
Recommended
Amtrak train hits pickup truck in upstate New York, 3 dead including child
Wrexham owners Ryan Reynolds and Rob McElhenney want to expand stadium capacity to 55,000
Fists fly as men in line for ride at popular Virginia park come to blows
Zimbabwe’s ZiG is the world’s newest currency
Shohei Ohtani's first walk
Family of Microsoft executive Brad Smith joins Seattle Mariners ownership group
Tennis legend Boris Becker discharged from bankruptcy court in England
Fury as Columbia University protesters stage insurrection
Links
- Jimmy Lai provided HK$1.5 million loan to activists, court hears
- Ukraine aid worker Chris Parry died unlawfully alongside Andrew Bagshaw, inquest hears
- Australian town of Marble Bar clocks 26 consecutive days over 43 degrees Celsius
- Mouse filmed tidying up man's shed every night
- Climate activists demand Christchurch include cruise ship emissions in targets
- Foreign Affairs Minister Winston Peters to resume 'Pacific reset' plan again
- Nine apologises for using digitally altered image of Animal Justice Party MP Georgie Purcell
- Ethnic army seizes city on Myanmar
- Ukraine aid worker Chris Parry died unlawfully alongside Andrew Bagshaw, inquest hears
- Doggy ballgowns, surveillance tech and cloning services for sale at China pet fair